Back to Research Hub
Atrium Therapeutics, Inc.
RNA
$11.76+0.21 (+1.82%)
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.
StreetsValue research for Atrium Therapeutics, Inc. (RNA)
Members get the full report for Atrium Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.